X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FRESENIUS KABI ONCO. NATCO PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 16.7 22.1 75.6% View Chart
P/BV x 18.0 3.1 579.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 NATCO PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
FRESENIUS KABI ONCO.
Mar-13
NATCO PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs877176 498.3%   
Low Rs42479 539.5%   
Sales per share (Unadj.) Rs223.437.7 592.9%  
Earnings per share (Unadj.) Rs31.15.1 610.0%  
Cash flow per share (Unadj.) Rs40.36.7 599.0%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.542.5 515.9%  
Shares outstanding (eoy) m33.07158.23 20.9%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.4 86.2%   
Avg P/E ratio x20.925.0 83.8%  
P/CF ratio (eoy) x16.118.9 85.3%  
Price / Book Value ratio x3.03.0 99.0%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,50420,135 106.8%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m1,128703 160.4%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m7,3895,963 123.9%  
Other income Rs m16718 928.3%   
Total revenues Rs m7,5565,981 126.3%   
Gross profit Rs m1,7931,430 125.4%  
Depreciation Rs m304258 118.0%   
Interest Rs m366-26 -1,408.5%   
Profit before tax Rs m1,2901,216 106.1%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m309342 90.2%   
Profit after tax Rs m1,027806 127.5%  
Gross profit margin %24.324.0 101.2%  
Effective tax rate %23.928.1 85.1%   
Net profit margin %13.913.5 102.9%  
BALANCE SHEET DATA
Current assets Rs m3,6815,102 72.2%   
Current liabilities Rs m3,1232,385 130.9%   
Net working cap to sales %7.645.6 16.6%  
Current ratio x1.22.1 55.1%  
Inventory Days Days89150 59.6%  
Debtors Days Days59113 51.8%  
Net fixed assets Rs m7,6855,148 149.3%   
Share capital Rs m331158 209.0%   
"Free" reserves Rs m6,6706,556 101.7%   
Net worth Rs m7,2596,732 107.8%   
Long term debt Rs m955952 100.3%   
Total assets Rs m11,95710,388 115.1%  
Interest coverage x4.5-45.8 -9.9%   
Debt to equity ratio x0.10.1 93.0%  
Sales to assets ratio x0.60.6 107.7%   
Return on assets %11.77.5 155.2%  
Return on equity %14.212.0 118.2%  
Return on capital %20.714.6 141.9%  
Exports to sales %39.474.5 52.8%   
Imports to sales %5.724.8 23.0%   
Exports (fob) Rs m2,9084,441 65.5%   
Imports (cif) Rs m4211,477 28.5%   
Fx inflow Rs m3,4455,298 65.0%   
Fx outflow Rs m7031,772 39.7%   
Net fx Rs m2,7433,525 77.8%   
CASH FLOW
From Operations Rs m1,4401,274 113.0%  
From Investments Rs m-1,089-1,204 90.5%  
From Financial Activity Rs m-353-196 179.9%  
Net Cashflow Rs m-1-126 1.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 81.0 1.8%  
Indian inst/Mut Fund % 7.8 0.3 2,613.3%  
FIIs % 16.6 9.6 173.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 9.1 285.7%  
Shareholders   25,395 42,599 59.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SANOFI INDIA  TORRENT PHARMA  STRIDES SHASUN LTD  CIPLA  ABBOTT INDIA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS